Notch2 Protein is a protein involved in key cellular signaling pathways relevant to neurodegenerative diseases. This page provides comprehensive information about its structure, normal biological function, and role in disease pathogenesis.
Notch2 Protein participates in critical cellular processes that, when dysregulated, contribute to neurodegeneration. Understanding this protein's function is essential for developing therapeutic interventions for Alzheimer's disease, Parkinson's disease, and related conditions.
| Notch2 Protein | |
|---|---|
| Protein Name | Notch2 |
| Gene | [NOTCH2](/genes/notch2) |
| UniProt ID | Q12983 |
| PDB Structure | 2OO9, 5M2Y, 6HD4 |
| Molecular Weight | 274 kDa (full length) |
| Subcellular Localization | Cell membrane, Nucleus (after cleavage) |
| Protein Family | Notch family (type I transmembrane receptor) |
Notch2 has a similar domain architecture to Notch1: an extracellular domain with EGF-like repeats and LNR domains, a transmembrane region, and an intracellular domain. The extracellular domain contains 36 EGF-like repeats and 3 LNR domains. Notch2 undergoes ligand-dependent proteolytic cleavage similar to other Notch receptors, releasing the NICD for nuclear translocation.
Notch2 regulates cell fate decisions during development and adult tissue homeostasis. It plays essential roles in neurogenesis, gliogenesis, and synaptic plasticity. In the nervous system, Notch2 is important for neural stem cell maintenance, oligodendrocyte differentiation, and synaptic function. It interacts with the canonical Notch signaling pathway to regulate transcription of target genes.
NOTCH2 mutations cause Hajdu-Cheney syndrome, a rare disorder characterized by progressive bone loss and neurological features. In Alzheimer's disease, Notch2 expression is altered and may interact with Aβ pathology. Notch2 also regulates genes involved in amyloid processing and neuronal survival under stress.
Notch2-targeting therapies are primarily being developed for cancer. Similar to Notch1, γ-secretase inhibitors block Notch2 activation but have limited clinical utility due to toxicity. Monoclonal antibodies against Notch2 are in development for various cancers.